Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 185

Results For "24"

2044 News Found

Launches and margin sustainability hold key for Glenmark: ICICI Direct
News | February 15, 2022

Launches and margin sustainability hold key for Glenmark: ICICI Direct

Key takeaways of Q3FY22 quarter & conference call highlights


Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
News | February 14, 2022

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct

Key takeaways of recent quarter & conference call highlights


OPPI-QCI announce awards to celebrate excellence in manufacturing facility 2021
News | February 11, 2022

OPPI-QCI announce awards to celebrate excellence in manufacturing facility 2021

The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24


Novavax Covid-19 vaccine well tolerated in paediatric population
Biotech | February 11, 2022

Novavax Covid-19 vaccine well tolerated in paediatric population

Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified


Glenmark launches nasal spray to treat Covid-19
News | February 09, 2022

Glenmark launches nasal spray to treat Covid-19

Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process


Thermo Fisher Scientific launches rapid environmental PCR testing solution
Medical Device | February 08, 2022

Thermo Fisher Scientific launches rapid environmental PCR testing solution

Rapid testing produces air sample results in 30 minutes


GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
News | February 08, 2022

GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22

EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.


Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
News | February 05, 2022

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021